Rapamune
Rapamune (sirolimus) is an immunosuppressive agent. It works by inhibiting T-lymphocyte activation and proliferation that occurs in response to antigenic and cytokine stimulation. It is used to prevent transplant rejection and to treat lymphangioleiomyomatosis, a rare progressive lung disease.
Dosage by Body Weight
Dosage must be individualized under the supervision of a transplant specialist. Routine monitoring of sirolimus whole blood trough concentrations is highly recommended. For renal transplant patients aged 13 or older weighing less than 50 kg, dosing is calculated using Body Surface Area (BSA). It should be taken consistently either with or without food.
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy in pediatric patients under 13 years of age have not been established.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy in pediatric patients under 13 years of age have not been established.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy in pediatric patients under 13 years of age have not been established.
- Body Weight
- 11-15 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy in pediatric patients under 13 years of age have not been established.
- Body Weight
- 16-20 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy in pediatric patients under 13 years of age have not been established.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | N/A | Safety and efficacy in pediatric patients under 13 years of age have not been established. |
| 5-7 kg | Not recommended | N/A | Safety and efficacy in pediatric patients under 13 years of age have not been established. |
| 8-10 kg | Not recommended | N/A | Safety and efficacy in pediatric patients under 13 years of age have not been established. |
| 11-15 kg | Not recommended | N/A | Safety and efficacy in pediatric patients under 13 years of age have not been established. |
| 16-20 kg | Not recommended | N/A | Safety and efficacy in pediatric patients under 13 years of age have not been established. |
Formulation
Purpose
Prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants, and the treatment of patients with Lymphangioleiomyomatosis (LAM).
Generic Name
SirolimusScheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.